加载中
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
常规交易时段
US$19.045
+US$0.195 · +1.03%
盘中时间采用ET。市场数据可能有所延迟。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日内区间
当前US$19.045
52周区间
当前US$19.045
盘中时间采用ET。市场数据可能有所延迟。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日内区间
当前US$19.045
52周区间
当前US$19.045
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB732.24万0.07%107.38亿 USD0.44%US$202.49+1.23%
AdvisorShares Psychedelics ETFPSIL173.49万3.94%4400.2万 USD1.84%US$20.375+0.42%
iShares MSCI Ireland ETFEIRL99.97万1.32%7504.44万 USD0.50%US$79.87+0.00%
Virtus Biotech Clinical Trials ETFBBC30.08万0.74%3876.9万 USD0.65%US$41.17+1.30%
Invesco Nasdaq Biotechnology ETFIBBQ10.8万0.10%1.11亿 USD0.19%US$33.895+1.38%
ProShares Ultra Nasdaq BiotechnologyBIB4.97万0.06%8707.88万 USD1.19%US$106.24+2.55%
First Trust IPOX Europe Equity Opportunities ETFFPXE1.05万0.22%471.23万 USD0.70%US$33.00+5.00%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
